In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Alectos Therapeutics Inc.

http://www.alectos.com

Latest From Alectos Therapeutics Inc.

Lost In The Middle: Why Value Added Products Need Better Pricing Mechanisms

Europe needs better pricing systems for so-called value added medicines if the market for such products is to be sustainable or attractive, Warrick Smith, director general of the British Generic Manufacturers Association, the BGMA, told Scrip.

Market Access

Corium names business chief

Menlo Park, California-based Corium, a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, has appointed Dr Joseph J Sarret to the newly created position of chief business officer. Reporting to Corium's president and CEO Peter D Staple, Dr Sarret will serve as a member of the company's executive leadership team with responsibility for developing and implementing Corium's business strategies, building new alliances and expanding existing ones, and pursuing new business initiatives that leverage Corium's advanced transdermal technologies and product candidates.

New EU guideline on development of modified-release formulations

The European Medicines Agency has agreed a new guideline on the development of modified-release dosage forms, describing the studies that will be needed to demonstrate the efficacy, safety and pharmacokinetic properties of formulations such as prolonged, delayed and multiphasic-release formulations of medicines.

Companies

Compounding Warning Letter Format Unchanged Since Legislation

FDA’s first two warning letters since draft compounding guidances may be another way to encourage outsourcer registration.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register